<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR><BR><BR>ADVERSE REACTIONS<BR>While clinical studies conducted with ACZONE™ Gel, 5%, for acne vulgaris did not demonstrate evidence of clinically significant anemia, an increased reticulocyte count and a decreased hemoglobin level were found in a G6PD deficient patient who had a complete blood count performed.  Only 25 patients with low plasma glucose 6-phosphate dehydrogenase activity treated with ACZONE™ Gel, 5%, were included in the clinical study program.Serious adverse events reported in patients treated with ACZONE™ Gel, 5%, during clinical trials included but were not limited to the following:Nervous system/Psychiatric – Suicide attempt, tonic clonic movements.Gastrointestinal – Abdominal pain, severe vomiting, pancreatitis.Other – Severe pharyngitisCombined contact sensitization/irritation studies with ACZONE™ Gel, 5%, in 253 healthy subjects resulted in at least 3 subjects with moderate erythema.  ACZONE™ Gel, 5%, did not induce phototoxicity or photoallergy in human dermal safety studies.ACZONE™ Gel, 5%, was evaluated for 12 weeks in four controlled studies for local cutaneous events in 1819 patients.  The most common events reported from these studies include oiliness/peeling, dryness, and erythema.  These data are shown by severity in Table 3 below.<BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" frame="box"><caption>Table 3 - Application Site Adverse Events by Maximum Severity from Four 12-Week, Vehicle-Controlled Studies</caption><BR><thead><BR><tr><th align="left" styleCode="BotruleLruleRruleToprule" valign="top"/><th align="center" colspan="3" styleCode="BotruleLruleRruleToprule" valign="top">ACZONE&#8482;(N=1819)</th><th align="center" colspan="3" styleCode="BotruleLruleRruleToprule" valign="top">Vehicle(N=1660)</th></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Application Site Event</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Mild</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Moderate</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Severe</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Mild</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Moderate</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Severe</td></tr><BR></thead><BR><tbody><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Erythema</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">9%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">5%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">&lt;1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">9%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">6%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">&lt;1%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Dryness</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">14%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">3%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">&lt;1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">14%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">4%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">&lt;1%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Oiliness/Peeling </td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">13%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">6%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">&lt;1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">15%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">6%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">&lt;1%</td></tr><BR></tbody><BR></table><BR><BR><BR>There were no significant differences in the adverse event rates between ACZONE™ Gel, 5%, and vehicle control treated patients.  The adverse events occurring in at least 1% of patients in either arm in the four vehicle controlled studies are presented in Table 4.<BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" frame="box"><caption>Table 4 - Adverse Events Occurring in at least 1% of Patients in Four Vehicle Controlled Studies</caption><BR><thead><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top"/><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">ACZONE&#8482;<br/>N=1819</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">Vehicle<br/>N=1660</td></tr><BR></thead><BR><tbody><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Application Site Reaction NOS</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">18%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">20%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Application Site Dryness</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">16%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">17%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Application Site Erythema</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">13%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">14%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Application Site Burning</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">2%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Application Site Pruritus</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Pyrexia</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Nasopharyngitis</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">5%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">6%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Upper Respiratory Tract Inf. NOS</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">3%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">3%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Sinusitis NOS</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">2%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Influenza</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Pharyngitis</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">2%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">2%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Cough</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">2%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">2%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Joint Sprain</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">1%</td></tr><BR><tr><td align="left" styleCode="BotruleLruleRruleToprule" valign="top">Headache NOS</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">4%</td><td align="center" styleCode="BotruleLruleRruleToprule" valign="top">4%</td></tr><BR></tbody><BR></table><BR><BR><BR>One patient treated with topical dapsone in the clinical trials had facial swelling which led to discontinuation of medication.In addition, 486 patients were evaluated in a 12 month safety study.  The adverse event profile in this study was consistent with that observed in the vehicle-controlled studies.<BR><BR><BR></P></DIV></HTML>